Reported 2 months ago
Warren Buffett's strategy of being greedy during market downturns is highlighted as the VIX spikes, signaling fear in the market. TransMedics Group (TMDX), a leader in organ care solutions with a 125% revenue increase in the first half of 2024, stands out as a prime candidate for investment if market prices drop. With an FDA-approved system for organ preservation that significantly improves transplant outcomes, TMDX is poised for further growth. However, investors are advised to wait for a price correction before buying, as current valuations may carry high risks.
Source: YAHOO